Our findings highlight CBP/EP300-BRDs as promising targetsfor autoimmune therapy, with these non-cytotoxic inhibitors offeringa potential complementary approach for RA and other TNF-α-mediatedinflammatory conditions. This evidence concerns the gene EP300 and rheumatoid arthritis.